Emerald | International Journal of Pharmaceutical and Healthcare Marketing | Table of Contents http://www.emeraldinsight.com/1750-6123.htm Table of contents from the most recently published issue of International Journal of Pharmaceutical and Healthcare Marketing Journal en-gb Tue, 26 Aug 2014 00:00:00 +0100 2014 Emerald Group Publishing Limited editorial@emeraldinsight.com support@emeraldinsight.com 60 Emerald | International Journal of Pharmaceutical and Healthcare Marketing | Table of Contents http://www.emeraldinsight.com/common_assets/img/covers_journal/ijphmcover.gif http://www.emeraldinsight.com/1750-6123.htm 120 157 The Changing Healthcare Landscape in the United States http://www.emeraldinsight.com/journals.htm?issn=1750-6123&volume=8&issue=3&articleid=17116498&show=abstract <strong>Abstract</strong><br /><br />Not available. Article literatinetwork@emeraldinsight.com (Vivek Pande) Tue, 26 Aug 2014 00:00:00 +0100 An International and Comparative Study of Perceived Justice in Mexican, Puerto Rican and Spanish Hospitals http://www.emeraldinsight.com/journals.htm?issn=1750-6123&volume=8&issue=3&articleid=17116494&show=abstract <strong>Abstract</strong><br /><br /><B>Purpose</B> - To test a construct of perceived justice and its dimensions in negative service encounters across Mexican, Puerto Rican and Spanish hospitals. Also to compare similarities and differences of perceived justice in negative service encounters in these countries.<B>Design/methodology/approach</B> - Includes Mexicans, Puerto Ricans and Spaniards who have experienced service failures at hospital settings. A descriptive research design was followed and a self-administered questionnaire was applied to gather the data from respondents. The researchers applied convenience sampling, and a pre-screening of respondents was included to verify that respondents were appropriate to participate in the study. A total number of 937 useable questionnaires were obtained from the hospital settings.<B>Findings</B> - The empirical findings across three Spanish speaking countries indicate that the construct of perceived justice in negative service encounters consists of merely 15 items, divided into three dimensions, namely: (i) distributional, (ii) interactional and (iii) procedural.<B>Research limitations/implications</B> - The empirical findings provide satisfactory validity and reliability across three countries, but there are acknowledged research limitations. These offer an opportunity for further research to verify or falsify the validity, reliability and generalization of the current findings.<B>Practical implications</B> - Service providers may use the three-dimensional construct of perceived justice as a guide when developing, implementing and managing processes and procedures of service failures in negative service encounters. <B>Originality/value</B> - The current international study in Mexico, Puerto Rico and Spain complements and fortifies previous research and existing theory of perceived justice in negative service encounters, and possible actions of complaint handling as well as service recovery. Article literatinetwork@emeraldinsight.com (Juan C Sosa Varela, Irma Magaña, Carmen Padin, Carmen Otero-Neira, Maria de los M. Santos Corrada, Goran Svensson) Tue, 26 Aug 2014 00:00:00 +0100 A Comparative Study of Reciprocity in International Physician Licensing http://www.emeraldinsight.com/journals.htm?issn=1750-6123&volume=8&issue=3&articleid=17116497&show=abstract <strong>Abstract</strong><br /><br /><B>Purpose</B> - Purpose: The purpose of this paper is to examine the international mobility of physicians by comparing the regulations governing the practice of foreign physicians in the U.S. and eight other countries. <B>Design/methodology/approach</B> - Design/methodology/approach: This is a comparative study of the regulations governing the practice of foreign physicians in eight countries: China, India, the Philippines, the U.K., Germany, Denmark, Israel, and Australia. Their requirements are then contrasted with the United States’ requirements for foreign physician licensure to evaluate the extent of reciprocity among these countries. We conclude the paper by outlining some recommendations to increase the international mobility of physicians in the future.<B>Findings</B> - Findings: The results indicate that licensure for U.S. physicians to practice in the nations above ranges from impossible (India), to difficult (China), to moderately difficult (U.K., Germany, Denmark), to easy and completely reciprocal (Australia, Israel, Philippines). <B>Originality/value</B> - Practical implications/originality/value: The results and recommendations in this study are a valuable starting point for further research and policy changes that will ensure a more reciprocal relationship between the U.S. and other countries, in terms of opportunities for international medical practice. Article literatinetwork@emeraldinsight.com (Vivek Pande) Tue, 26 Aug 2014 00:00:00 +0100 The Learned Intermediary Doctrine: The Case of Advertising Medicine and Medical Devices in the United States http://www.emeraldinsight.com/journals.htm?issn=1750-6123&volume=8&issue=3&articleid=17116495&show=abstract <strong>Abstract</strong><br /><br /><B>Purpose</B> - This paper examines a unique marketing and legal problem that manufacturers of prescription drugs and medical devices face in the United States, under the theory of "overpromotion" and the Learned Intermediary Doctrine (the LID), and suggests a solution to the problem. <B>Design/methodology/approach</B> - The study employs a critical review of the literature and decided legal cases to analyze the problem of direct-to-consumer (DTC) advertising of prescription drugs and medical devices under the LID and "overpromotion" doctrines. <B>Findings</B> - The study suggests a different approach to advertising drugs that divides the audiences into primary and secondary targets in order to immunize drug and medical device manufacturers against liability. <B>Research limitations/implications</B> - Because the laws guiding advertising are different in different countries, the findings of this study are relevant only to the U.S. market. <B>Practical implications</B> - The paper gives practical guidance on an alternative communication strategy that could immunize drugs and medical device manufacturers against liability.<B>Originality/value</B> - The study uses knowledge of law and marketing to tackle an issue that, even though, is useful and relevant is rarely discussed in the marketing literature. Article literatinetwork@emeraldinsight.com (P. Sergius Koku) Tue, 26 Aug 2014 00:00:00 +0100 The False Claims Act: A Review and Policy Recommendations http://www.emeraldinsight.com/journals.htm?issn=1750-6123&volume=8&issue=3&articleid=17116493&show=abstract <strong>Abstract</strong><br /><br /><B>Purpose</B> - The False Claims Act (FCA) has been applied against pharmaceutical companies by the U.S. government to combat marketing fraud including kickbacks, improper pricing, and off-label promotion. The authors review FCA settlements and challenges facing the industry to suggest the motivation behind firms’ alleged fraudulent activity. The interests of the U.S. government and medical professionals are also considered. Changes to the law governing pharmaceutical marketing practices are recommended.<B>Design/methodology/approach</B> - Cases settled under the FCA between 2005 and 2012 were identified by accessing the U.S. Department of Health and Human Services (DHHS) Corporate Integrity Agreements website and annual reports and the quitamhelp.com website. Case details were collected from U.S. Department of Justice press releases, DHHS annual reports, and case documents in the PACER database.<B>Findings</B> - Of the settled cases in the final sample, improper pricing practices were evident in 33% of the cases; off-label promotion in 52%; and both in 15% of the cases. Forty-eight percent of the alleged fraudulent marketing activity occurred within the brands’ first year and 68% within the first two years on the market. Reported settlements ranged from $4 million to $4.3 billion.<B>Originality/value</B> - This research simultaneously considers business issues facing the pharmaceutical industry and alleged fraudulent marketing activity to recommend changes to the law governing drug promotion. Changes have the potential to improve the balance between the respective interests of industry, medicine, and government and to improve compliance and patient care in the future. Article literatinetwork@emeraldinsight.com (Mary E. Schramm, Jennifer L. Herbst, Angela Mattie) Tue, 26 Aug 2014 00:00:00 +0100 The Effect of Affordable Care Act on the Competition in the Post Patent Ethical Drug Market http://www.emeraldinsight.com/journals.htm?issn=1750-6123&volume=8&issue=3&articleid=17116496&show=abstract <strong>Abstract</strong><br /><br /><B>Purpose</B> - US policy makers have been looking at various ways to curb rising health care costs in USA, including ways to promote the use of generic drugs in lieu of brand drugs. In this broader context, the implementation of Patient Protection and Affordable Care Act (ACA) in December 2013 will introduce major changes in the pharmaceutical market. This paper is designed to study the post patent ethical drug market and simulate the impact of ACA on individuals, healthcare providers and pharmaceutical firms. <B>Design/methodology/approach</B> - To fully understand the impact of such policy changes, we develop a structural model to study consumers’ buying behavior and firm competition in the post patent ethical drug markets. We use the estimated model parameters to conduct four policy simulations to illustrate the effect of Obamacare on: 1) increasing the relative size of price insensitive segment; 2) reducing price sensitivity in the price sensitive segment; 3) providing brand price discount to Medicare patients previously in the "donut hole"; and 4) the effect of change in people’s attitude towards generics. <B>Findings</B> - Our model estimation reveals two classes of consumers with different price sensitivities. This heterogeneity explains the increase in the brand price after generic entry. We identify consumers’ switching costs between generic and brand drugs, as well as among different generics. From the policy simulation, we find that except the closure of Medicare donut hole, all other policy changes lead to increased usage of the focal molecule, and the efforts to increase insurance coverage and reduce the out of pocket payment for prescription drugs lead to increase in firm profit. <B>Originality/value</B> - This paper is the first to illustrate the potential policy effect of Obamacare through a structural model on post patent ethical drug market. Article literatinetwork@emeraldinsight.com (Yu Yu, Yi Zhao) Tue, 26 Aug 2014 00:00:00 +0100